Striatal Cholinergic Interneurons In Huntington'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Striatal Cholinergic Interneurons In Huntington'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
- Represent ~1-2% of striatal neurons
- Large, aspiny neurons with extensive dendritic arborizations
- Uniformly distributed throughout the caudate nucleus and putamen
- Choline acetyltransferase (ChAT) - synthetic enzyme
- Vesicular acetylcholine transporter (VAChT)
- Acetylcholinesterase (AChE) - degradative enzyme
- Pause responses to salient stimuli
- Integration of cortical and thalamic inputs
- Regulation of medium spiny neuron (MSN) activity
- Involved in:
- Motor learning
- Reward processing
- Attention
- Early and progressive loss of cholinergic interneurons
- Loss correlates with:
- Cognitive deficits
- Psychiatric symptoms
- Motor dysfunction
- Reduced ChAT activity
- Decreased acetylcholine release
- Altered muscarinic receptor binding
- VAChT dysfunction
- Mutant huntingtin (mHTT) aggregation
- Excitotoxicity from cortical inputs
- Energy metabolism deficits
- Neuroinflammation
- Contributes to chorea development
- Alters motor learning
- Affects voluntary movement initiation
- Working memory impairment
- Attention deficits
- Executive dysfunction
- Depression
- Anxiety
- Irritability
- Acetylcholinesterase inhibitors (limited efficacy)
- Muscarinic receptor modulators
- Anti-excitotoxic agents
- Cholinergic stem cell transplantation
- Gene therapy for cholinergic function
- mHTT lowering in cholinergic neurons
Striatal Cholinergic Interneurons In Huntington'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Striatal Cholinergic Interneurons In Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ferrante RJ, et al. (1985). Selective sparing of a class of striatal neurons in Huntington's disease. Science. PMID:3871968.
- Smith R, et al. (2006). Cholinergic dysfunction in Huntington disease. J Neurol Neurosurg Psychiatry. PMID:16501505.
- Zuccato C, et al. (2010). Molecular pathogenesis of Huntington's disease: transcription factors and pathways. Prog Neuropsychopharmacol Biol Psychiatry. PMID:20097214.
- Walker FO. (2007). Huntington's disease. Lancet. PMID:17240277.
- Raymond LA, et al. (2011). Striatal signaling in Huntington's disease. Brain Res Bull. PMID:21477656.